Compare · ALC vs BLCO
ALC vs BLCO
Side-by-side comparison of Alcon Inc. (ALC) and Bausch + Lomb Corporation (BLCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALC and BLCO operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- ALC is the larger of the two at $33.38B, about 6.1x BLCO ($5.51B).
- Over the past year, ALC is down 23.7% and BLCO is up 29.4% - BLCO leads by 53.1 points.
- BLCO has hit the wire 16 times in the past 4 weeks while ALC has been quiet.
- ALC has more recent analyst coverage (25 ratings vs 18 for BLCO).
- Company
- Alcon Inc.
- Bausch + Lomb Corporation
- Price
- $66.81+0.32%
- $15.48+0.72%
- Market cap
- $33.38B
- $5.51B
- 1M return
- +2.11%
- -3.25%
- 1Y return
- -23.67%
- +29.43%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- 2022
- News (4w)
- 0
- 16
- Recent ratings
- 25
- 18
Alcon Inc.
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; and EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Latest ALC
- SEC Form SD filed by Alcon Inc.
- SEC Form 6-K filed by Alcon Inc.
- New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
- Alcon Announces Results of 2026 Annual General Meeting
- Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in Canada
- Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026
- SEC Form 6-K filed by Alcon Inc.
- Alcon Publishes Agenda for 2026 Annual General Meeting
- Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
- Alcon Surpasses 175 Million IOLs Implanted Globally
Latest BLCO
- SEC Form SD filed by Bausch + Lomb Corporation
- Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
- Director Von Eschenbach Andrew C. was granted 15,842 shares, increasing direct ownership by 22% to 86,656 units (SEC Form 4)
- Director Ross Thomas W. Sr. was granted 15,842 shares, increasing direct ownership by 23% to 85,233 units (SEC Form 4)
- Director Robertson Russel C was granted 15,842 shares, increasing direct ownership by 20% to 94,260 units (SEC Form 4)
- Director Paulson John was granted 15,842 shares, increasing direct ownership by 21% to 89,823 units (SEC Form 4)
- Director Ling Karen was granted 15,842 shares, increasing direct ownership by 35% to 61,518 units (SEC Form 4)
- Director Kavanagh Sarah B was granted 15,842 shares, increasing direct ownership by 30% to 69,541 units (SEC Form 4)
- Director Collis Steven H was granted 15,842 shares, increasing direct ownership by 61% to 42,003 units (SEC Form 4)
- Director Bernier Nathalie D. was granted 15,842 shares, increasing direct ownership by 23% to 85,505 units (SEC Form 4)